scholarly journals INTERDISCIPLINARY PERIPARTUM CARE OF THE PATIENT WITH DIASTOLIC HEART FAILURE IN NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

2017 ◽  
Vol 69 (11) ◽  
pp. 2118
Author(s):  
Katherine Beutner ◽  
Euan Ashley ◽  
Matthew Wheeler ◽  
Victoria Parikh ◽  
Lindsay Wheeler ◽  
...  
Keyword(s):  
Heart Failure ◽  
Hypertrophic Cardiomyopathy ◽  
Diastolic Heart Failure ◽  
Obstructive Hypertrophic Cardiomyopathy

scholarly journals Serum levels of cardiotrophin-1 in patients with obstructive hypertrophic cardiomyopathy and in patients with severe left ventricular dysfunction

2021 ◽  
Vol 36 (2) ◽  
pp. 70-75
Author(s):  
O. N. Ogurkova ◽  
E. N. Pavlyukova ◽  
T. E. Suslova
Keyword(s):  
Heart Failure ◽  
Hypertrophic Cardiomyopathy ◽  
Blood Serum ◽  
Diastolic Heart Failure ◽  
Left Ventricular ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Lv Dysfunction ◽  
Wide Range ◽  
Obstructive Hypertrophic Cardiomyopathy

Relevance. Cardiotrophin-1 (CT-1) is a member of interleukin-6 (IL-6) superfamily and is associated with cardiovascular pathology. The production of CT-1 increases in response to myocardial wall stretching and increase in its rigidity and is also modulated by a wide range of neurohormones and peptides, which allows to monitor CT-1 as a marker of biomechanical stress. However, the prognostic significance of CT-1 in patients with diastolic heart failure with hypertrophic cardiomyopathy (HCM) remains poorly understood.Objective. To study the blood serum cardiotrophin-1 contents and their relationships with NT-proBNP in patients with obstructive hypertrophic cardiomyopathy and in patients with severe left ventricular (LV) dysfunction.Material and Methods. The study comprised a total of 76 patients with obstructive HCM and 31 patients with severe LV dysfunction. The group of patients with HCM comprised patients with obstructive form; the group of patients with severe LV dysfunction included patients with the third type of post-infarction LV remodeling and ejection fraction (EF) of less than 30%. The determination of cardiotrophin-1 and highly sensitive C-reactive protein was carried out by the enzyme immunoassay. The study of NT-proBNP content in blood serum was performed by multiplex immunoassay using the FLEXMAP 3D Luminex Corporation system.Results. The content of cardiotrophin-1 in the blood serum of patients with obstructive HCM was higher than in the group of patients with severe LV dysfunction. The study of NT-proBNP concentrations in the blood serum showed increases in the content in both groups of patients. The median concentrations of NT-proBNP and C-reactive protein in patients with severe LV dysfunction were increased compared to the median concentration in patients with obstructive HCM.Conclusion. The study showed an increase in cardiotrophin-1 content in the blood serum in patients with obstructive HCM with chronic diastolic heart failure. The increase in cardiotrophin-1 content was directly associated with the increase in NTproBNP level in patients with obstructive HCM with chronic diastolic heart failure.

A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic Cardiomyopathy

2021 ◽  
Author(s):  
Cynthia Burstein Waldman ◽  
Anjali Owens
Keyword(s):  
Heart Failure ◽  
Blood Flow ◽  
Hypertrophic Cardiomyopathy ◽  
Well Being ◽  
Daily Activities ◽  
Shortness Of Breath ◽  
Plain Language ◽  
Clinical Trial Registration ◽  
Obstructive Hypertrophic Cardiomyopathy ◽  
Active Substances

Mavacamten is an investigational therapy for the treatment of hypertrophic cardiomyopathy (HCM), a condition where the heart muscle wall thickens, becomes stiff, and makes it harder for the heart to pump blood. In obstructive HCM (sometimes referred to as oHCM or HOCM), the thickened muscle also blocks blood flow from the heart. The EXPLORER-HCM trial compared mavacamten to placebo (a pill with no medicine/active substances) in symptomatic people with obstructive HCM who had exercise limitations and suffered from shortness of breath, tiredness, palpitations, and chest pain. The study showed that mavacamten reduced the obstruction that restricts blood flow and improved people’s symptoms, well-being, and ability to participate in daily activities. Side effects, such as irregular heartbeat, palpitations, rapid heartbeat, and heart failure, were similar for people who received mavacamten or placebo. To read the full Plain Language Summary of this article, click on the View Article button above and download the PDF. Clinical Trial Registration: NCT03470545 ( ClinicalTrials.gov )

Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy

2019 ◽  
Vol 35 (2) ◽  
pp. 214-222 ◽  
Author(s):  
Ji-Hun Jang ◽  
Sung-Hee Shin ◽  
Yong Soo Beak ◽  
Kyu Yong Ko ◽  
Sung Woo Kwon ◽  
...  
Keyword(s):  
Heart Failure ◽  
Hypertrophic Cardiomyopathy ◽  
Obstructive Hypertrophic Cardiomyopathy

Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy

2006 ◽  
Vol 8 (2) ◽  
pp. 115-121 ◽  
Author(s):  
Dirk Westermann ◽  
Björn C. Knollmann ◽  
Paul Steendijk ◽  
Susanne Rutschow ◽  
Alexander Riad ◽  
...  
Keyword(s):  
Heart Failure ◽  
Hypertrophic Cardiomyopathy ◽  
Diastolic Heart Failure ◽  
Familial Hypertrophic Cardiomyopathy

Clinical features of hypertrophic cardiomyopathy in the young

2002 ◽  
Vol 12 (2) ◽  
pp. 147-152 ◽  
Author(s):  
Eva Bruno ◽  
Héctor Maisuls ◽  
Ernesto Juaneda ◽  
Eduardo Moreyra ◽  
Luis E. Alday
Keyword(s):  
Heart Failure ◽  
Hypertrophic Cardiomyopathy ◽  
Young Patients ◽  
Total Mortality ◽  
Older Children ◽  
Congenital Cardiac Defects ◽  
Septal Thickness ◽  
Congenital Cardiac Disease ◽  
Obstructive Hypertrophic Cardiomyopathy ◽  
Older Populations

Background: We analysed the experience with hypertrophic cardiomyopathy in two paediatric centres to establish the differences from older patients. Methods: Out of 45 young patients seen from 1974 to 1999, we included 38. Criterions for exclusion were secondary forms, or association with severe congenital cardiac disease which could alter the outcome. Results: The patients presented at the age of 5.7 years, and were followed for 7.0 years. The 34 patients referred because of a murmur or cardiomegaly were older than the four with heart failure, presenting at 6.2 as opposed to 2.1 years of age, p = 0.08. Of the patients, 29 (76%) had primary cardiomyopathy, while 9 (24%) had secondary forms associated with Noonan's and LEOPARD syndromes. Familial tendency was ascertained in 7 patients (18%). The septal thickness in mm/m2 at presentation was greater in patients under 2 years than in older children (29 vs 18, p = 0.02). Obstructive hypertrophic cardiomyopathy was found in 17 patients (45%), with six of these having mild associated congenital cardiac defects. Nine had symptomatic arrhythmias. Overall, treatment was medical in 31, with DDD pacing used in 5, and surgery, radiofrequency ablation, and transplantation in one patient each. Total mortality was 24%, at a rate of 4.3% per year. Four patients died in heart failure and 5 had sudden death. Those in failure were significantly younger (p = 0.01). Conclusions: Hypertrophic cardiomyopathy in the young is characterized by referral for murmur or heart failure; frequent secondary forms; the obstructive variant being as common as the nonobstructive form; a mortality rate similar to that for adults attending tertiary centres; and less frequent familial forms than in older populations.

Sign in / Sign up

Export Citation Format

Share Document